Gamidov S I, Popova A Yu, Shatylko T V, Mammaev R U
National Medical Research Center of Obstetrics, Gynecology and Perinatology named after V.I. Kulakov of the Ministry of Health of Russia, Moscow, Russia.
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia, Moscow, Russia.
Urologiia. 2025 Jul(3):48-52.
To evaluate the effect of a drug based on bovine testicular polypeptides (Testiwell) on sperm parameters and sperm DNA fragmentation index in patients with idiopathic male infertility.
A total of 100 men with a diagnosis of infertility were included in the study. They received Testiwell intramuscularly once a week for 10 weeks. Before and after treatment, basic sperm parameters according to WHO criteria and sperm DNA fragmentation index using the TUNEL method were assessed. Statistical analysis included Shapiro-Wilk, Wilcoxon, paired Student's t-test, and McNemar's test.
The median age of patients was 32 years. Significant improvement was noted in the proportion of morphologically normal sperm (p<0.001), concentration of morphologically normal sperm (from 1.16 to 1.55 million/ml, p=0.048). A decrease in sperm DNA fragmentation index was observed (from 20.8% to 17.8%, p<0.001), a reduction in the frequency of oligozoospermia from 34% to 22% (p=0.0047), and a decrease in the proportion of patients with increased DNA fragmentation index from 79% to 67% (p=0.0013). In patients with oligozoospermia at baseline, the median increase in concentration was 142%, while in those with asthenozoospermia an increase in motility by 77% was seen, and in men with high levels of DNA fragmentation, a decrease in DNA fragmentation index by 15.5% was found.
Testiwell demonstrated the ability to positively influence not only quantitative but also qualitative sperm parameters, including morphology and sperm DNA fragmentation. Proposed mechanisms of action include regulation of protamination, reduction of apoptosis, and immunologically mediated effects on sperm maturation. The obtained data are consistent with previously described effects of polypeptide drugs in preclinical models and expand the possibilities of using the Testiwell for various forms of male infertility, including assisted reproduction techniques failures.
Testiwell significantly improves morphological and molecular parameters of spermatogenesis in patients with male infertility. It can be used both in the basic therapy of idiopathic infertility and, possibly, in cases of miscarriage and inefficiency of assisted reproduction techniques.
评估一种基于牛睾丸多肽的药物(Testiwell)对特发性男性不育患者精子参数及精子DNA碎片化指数的影响。
本研究共纳入100例诊断为不育的男性。他们每周接受一次Testiwell肌肉注射,共10周。治疗前后,根据世界卫生组织标准评估基本精子参数,并使用TUNEL法评估精子DNA碎片化指数。统计分析包括Shapiro-Wilk检验、Wilcoxon检验、配对t检验和McNemar检验。
患者的中位年龄为32岁。形态正常精子的比例有显著改善(p<0.001),形态正常精子的浓度也有改善(从116万/ml增至155万/ml,p=0.048)。观察到精子DNA碎片化指数下降(从20.8%降至17.8%,p<0.001),少精子症的发生率从34%降至22%(p=0.0047),DNA碎片化指数升高的患者比例从79%降至67%(p=0.0013)。基线时为少精子症的患者,浓度中位数增加了142%;弱精子症患者的精子活力增加了77%;DNA碎片化水平高的男性,DNA碎片化指数下降了15.5%。
Testiwell不仅对精子数量参数,而且对包括形态和精子DNA碎片化在内的质量参数都有积极影响。其作用机制包括鱼精蛋白调节、细胞凋亡减少以及对精子成熟的免疫介导作用。所得数据与之前在临床前模型中描述的多肽药物作用一致,并扩大了Testiwell在各种男性不育症(包括辅助生殖技术失败)中的应用可能性。
Testiwell显著改善男性不育患者精子发生的形态和分子参数。它可用于特发性不育的基础治疗,也可能用于流产病例及辅助生殖技术无效的情况。